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REVIEW CURRENTOPINION Dendritic cell analysis in primary immunodeficiency Copyright 
www.co-allergy.coma b aVenetia Bigley , Dawn Barge , and Matthew CollinPurpose of review
Dendritic cells are specialized antigen-presenting cells which link innate and adaptive immunity, through
recognition and presentation of antigen to T cells. Although the importance of dendritic cells has been
demonstrated in many animal models, their contribution to human immunity remains relatively unexplored in vivo.
Given their central role in infection, autoimmunity, and malignancy, dendritic cell deficiency or dysfunction
would be expected to have clinical consequences.
Recent findings
Human dendritic cell deficiency disorders, related to GATA binding protein 2 (GATA2) and interferon
regulatory factor 8 (IRF8) mutations, have highlighted the importance of dendritic cells and monocytes in
primary immunodeficiency diseases and begun to shed light on their nonredundant roles in host defense
and immune regulation in vivo. The contribution of dendritic cell and monocyte dysfunction to the
pathogenesis of primary immunodeficiency disease phenotypes is becoming increasingly apparent.
However, dendritic cell analysis is not yet a routine part of primary immunodeficiency disease workup.
Summary
Widespread uptake of dendritic cell/monocyte screening in clinical practice will facilitate the discovery of
novel dendritic cell and monocyte disorders as well as advancing our understanding of human dendritic
cell biology in health and disease.
Keywords
dendritic cell, GATA binding protein 2, immunodeficiency, interferon regulatory factor 8, monocyteaHuman Dendritic Cell Laboratory, Institute of Cellular Medicine, New-
castle University and bBlood Sciences Flow Cytometry Laboratory, New-
castle upon TyneHospitals NHS Foundation Trust, Newcastle upon Tyne,
UK
Correspondence to Dr Venetia Bigley, MD, PhD, Human Dendritic Cell
Lab, Room MG261, Institute of Cellular Medicine, Ground Floor William
LeechBuilding, Newcastle University Medical School, Framlington Place,
Newcastle upon Tyne NE2 4HH, UK. Tel: +44 191 282 1570;
e-mail: venetia.bigley@ncl.ac.ukINTRODUCTION
Much of our knowledge of dendritic cell biology is
inferred from mouse models and human in-vitro sys-
tems, which may not reflect the steady state and
provide a limited understanding of host defense in
the intact human. The analysis of dendritic cells in
primary immunodeficiencydisease (PID)hasprovided
new diagnostic tools and revealed new clinical syn-
dromes in addition to providing a unique opportunity
to probe the function of human dendritic cells in vivo.
In this review, we explore what is known about
dendritic cells and monocytes in PID, highlight the
recently described dendritic cell deficiency syn-
dromes related to GATA binding protein 2 (GATA2)
and interferon regulatory factor 8 (IRF8) mutations,
suggest a practical solution to dendritic cell analysis
in clinical practice, and speculate how best to fur-
ther our understanding of dendritic cells in PID and
immunity in general.Curr Opin Allergy Clin Immunol 2016, 16:530–540
DOI:10.1097/ACI.0000000000000322
This is an open access article distributed under the Creative Commons
Attribution License 4.0 (CCBY), which permits unrestricted use, distri-
bution, and reproduction in any medium, provided the original work is
properly cited.HUMAN DENDRITIC CELL BIOLOGY
Dendritic cells are bone marrow derived, specialized
antigen-presenting cells (APCs), positioned within
the immune system to bridge innate and adaptive© 2016 Wolters Kluwer immunity [1]. They are present in almost all tissues
wherein they detect pathogens and process extra-
cellular and intracellular antigen for presentation
to T cells in the context of major histocompatibility
complex (MHC) molecules. Populations ofperipheral
tissue dendritic cells, upon pathogen detection,
become activated and migrate to T cell areas of drain-
ing lymph nodes (LNs) where they stimulate antigen-
specific T cell responses to initiate immunity or tol-
erance. These are termed ‘migratory dendritic cells’Health, Inc. All rights reserved.
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KEY POINTS
 Dendritic cells play a central role in immunity and
tolerance but little is known of their contribution to
immune dysfunction in PID.
 Dendritic cell deficiency syndromes have recently been
described in the context of GATA2 and IRF8 mutations,
which highlight their importance in PID.
 The adoption of dendritic cell screening into clinical
diagnostic laboratories will provide critical information
for diagnostics and pathophysiology.
 Dendritic cell studies in PID offer a unique opportunity
to advance our understanding of dendritic cell biology
in humans.
Dendritic cell analysis in primary immunodeficiency Bigley et al.[2]. In addition to their ‘educator’ role, dendritic cells
can perform as effector cells, with the ability to
secrete cytokines and growth factors to manipulate
the tissue environment [3]. Although a prominent
role of dendritic cells is the polarization of naı¨ve T
cells, they are also able to interact with other immune
cells including B and natural killer (NK) lymphocytes
and innate lymphoid cells (ILCs) [4].DENDRITIC CELLS AS A DISTINCT
HEMATOPOIETIC LINEAGE
Based on in-vitro observations [5], it was previously
thought that dendritic cells were derived from mono-
cytes.Howevermultiplelinesofevidenceindicatethat,
atleastinthesteadystate,dendriticcellsarisethrougha
dedicated pathway of differentiation [6] (Fig. 1). In
human gene expression studies, dendritic cells form
a separate cluster from monocytes and macrophages
[7,8]andlineagetracing inmiceconfirmstheirdistinct
identities [9]. This distinction breaks down in inflam-
mation when inflammatory dendritic cells arise from
monocytes [10]. It is likely that in-vitro monocyte-
derived dendritic cells (mo-DCs) are surrogates for
these inflammatory dendritic cells.CLASSIFICATION OF DENDRITIC CELLS,
MONOCYTES, AND MACROPHAGES
A recent consensus study [11] has defined the
nomenclature of dendritic cells, monocytes, and
macrophages, based on ontogeny (monocyte or
dendritic cell lineage), anatomical location, and
surface antigen expression: two myeloid (or conven-
tional/classical) dendritic cell subsets are defined as:
cDC1, expressing CD141/BDCA3, Clec9A, XCR1;
and cDC2, expressing CD11c, CD1c/BDCA1, in
humans. The third dendritic cell subset comprises
plasmacytoid dendritic cells (pDCs) expressing Copyright © 2016 Wolters Kluwe
1528-4050 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseCD123, CD303/BDCA2, and CD304/BDCA4.
Human monocytes, representing 10–20% of PBMC,
are defined by their relative expression of CD14 and
CD16 as classical monocytes (CD14þCD16), inter-
mediate monocytes (CD14þCD16þ), and nonclass-
ical monocytes (CD14lowCD16þ) (Fig. 1). All
dendritic cells and monocytes are found in the
peripheral blood. In non-lymphoid tissues (e.g. epi-
thelia), there are usually cDC1 and cDC2, but no
pDCs in the steady state [12]. In lymph nodes, both
migratory and resident dendritic cell subsets are
found, including pDCs [2]. Most tissues contain
macrophage populations composed of both mono-
cyte-derived cells, with a rapid turnover, and fixed
macrophages that persist for many years, independ-
ently of the bone marrow. RUNX3þ cells of the
epidermis are also self-renewing and capable of sur-
viving independently of the bone marrow. How-
ever, unlike fixed macrophages, lymphoid cells are
able to leave the epidermis and mature into den-
dritic cells that enter the T cell zones of LNs (Fig. 1).
Macrophages are CD11c negative, gain expression of
CD163, LYVE-1, and FXIIIa, and are autofluorescent
because of accumulation of pigment such as lip-
ofuscin and melanin granules.GENETIC CONTROL OF DENDRITIC CELL
DEVELOPMENT AND FUNCTION
Dendritic cells and monocytes develop in the bone
marrow under the control of distinct transcription
factors. They develop discrete functions owing to
their expression of particular pattern recognition
receptors (PRRs) and elaboration of specialized
secretory products (Fig. 2).
cDC1 are dependent on BATF3 and IRF8 for
development [13], have superior cross-presenting
ability via Clec9a and secrete TNFa, IFNg and IFNl
more abundantly than IL-12p40 on TLR3 ligation
[14–16].
cDC2 require IRF4 and KLF4 expression for
differentiation [17,18]. They express TLR1, 2, 4, 5,
and 8, produce IL-12 [19] to prime CD4þ Th1 cells,
proinflammatory cytokines IL-1b, TNFa, IL-23 and
anti-inflammatory IL-10, depending on their
location and environment. They variably possess
many other functional receptors (e.g. Clec7A,
Clec6a, CD205) and can generate Th17 or Th2
responses to fungal antigens or allergens, respect-
ively [20]. Tissue cDC2 can detect glycolipid anti-
gens of mycobacteria through CD1a expression [21].
pDCs are dependent on transcription factors
RUNX2, E2-2, BCL11A, IRF7, and IRF8 [22–24].
Through TLR7 and TLR9 ligation, they are the major
IFNa producing cells in response to viral infection.
pDC can activate both Th1 and Th2 CD4þ responsesr Health, Inc. All rights reserved.
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FIGURE 1. Human dendritic cell subsets and their ontogeny. Human dendritic cells are derived from hematopoietic stem cells
in the bone marrow through a series of as yet undefined progenitors and precursors under the control of specific transcription
factors. In the mouse model, dendritic cell differentiation occurs through the macrophage and dendritic cell precursor (MDP)
and subsequently common dendritic cell precursor (CDP) and predendritic cell, but this path is as yet undefined in humans.
Differentiated monocyte and dendritic cell subsets circulate in peripheral blood and can be found as resident cells in lymphoid
tissue. In skin, monocyte-derived cells, cDC1, cDC2, tissue macrophages, and lymphoid cells can be found. On activation,
cDC1, cDC2, and lymphoid cells can migrate via lymphatics to draining lymph nodes where they are distinguishable from
resident cells. AK2, adenylate kinase 2; BATF3, basic leucine zipper transcriptional factor ATF-like 3; cMoP, common
monocyte progenitor; E2-2/TCF4, transcription factor 4; GFI1, growth factor independent 1; GMP, granulocyte macrophage
progenitor; HSC, hematopoietic stem cell; IKZF1, Ikaros family zinc finger 1; KLF4, Kruppel-like factor 4; MLP, multipotent
lymphoid progenitor.
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CD1c, CD11b, CD11c,
SIRPα
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CD304, CD45RA
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TF IRF8, BATF3, ID2 IRF4 IRF8, E2.2, RUNX2 RUNX3, ID2 KLF4
Location Blood, lymph and non-lymph tissue
Blood, lymph and non-
lymph tissue Blood and lymph tissue Epidermis, mucosae Tissue inflammation
TLRs TLR3 (TLR8) TLR8 (TLR7, TLR9,TLR4) TLR7, TLR9 TLR4, TLR9 TLR4, TLR9
Cytokines IFN lambda (TLR3) 
IL-12, IL-1b, TNFα
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Anti-fungal
Regulatory Treg
induction after viral
infection (HIV) via IDO
production
Anti-viral
Anti-fungal
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FIGURE 2. Phenotype and function of human dendritic cell subsets. Characteristic phenotype, transcription factor
requirements, Toll-like receptor (TLR) expression, cytokine production, T cell interactions, and biological roles of human
dendritic cell subsets. IDO, indolamine 2,3-dioxygenase; RUNX2/3, runt-related transcription factor 2/3; SIRPa, signal
regulatory protein alpha.
Dendritic cell analysis in primary immunodeficiency Bigley et al.and may induce Treg differentiation after viral infec-
tion and in the thymus [25].
Langerhans cells are dependent on RUNX3 and
ID2 and require IL-34 and TGFb for development
[26,27]. In inflammation, lymphoid cells can
respond to selected intracellular pathogens and
viruses and migrate to T cell areas of draining LNs
under the influence of TNF and IL-1b [28] and
secrete IL-15. They appear to maintain tolerance
to commensals through presentation of antigen in
the context of CD1a and Treg induction [29].
mo-DCs are found in inflammatory tissues. In
response to microbial challenge, monocytes down-
regulate CD14, upregulate dendritic cell markers
including CD1a and CD1c, and are able to activate
naı¨ve T cells. In tissues, they synthesize inflamma-
tory cytokines including IL-12, TNFa, IL-1b, IL-6, IL-
23, inducible nitric oxide synthase (iNOS) [30] and
stimulate Th1, Th2, or Th17 responses [31].DENDRITIC CELLS IN PRIMARY
IMMUNODEFICIENCY DISEASE
Dendritic cells may be reduced in number, defective
in function, or both (Table 1). Three syndromes Copyright © 2016 Wolters Kluwe
1528-4050 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseassociated with dendritic cell and monocyte
deficiency have been identified by profiling patients
with unexplained immunodeficiency. Heterozy-
gous mutations in GATA2 constitute the largest
group of cases and patients often survive undetected
into adulthood [32–34]. Biallelic IRF8 deficiencies
present at a young age with susceptibility to infec-
tion and myeloproliferation, similar to the IRF8-
knock-out mouse, whereas mono-allelic IRF8
mutation was identified in an adult cohort with
mycobacterial disease and represents a more subtle
hypomorphic phenotype [35].GATA2 mutation
Constitutive heterozygous GATA2 mutation causes
a complex disorder with a wide spectrum of age and
phenotype at presentation and is associated with
several clinically described syndromes including
Emberger syndrome (primary lymphedema and
MDS/AML), familial MDS/AML, and MonoMac
(monocytopenia with mycobacterium avium com-
plex). Extra-hematopoietic effects include congen-
ital deafness, primary lymphedema, autoimmunity,
and HPV-driven malignancies. In the hematopoieticr Health, Inc. All rights reserved.
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Dendritic cell analysis in primary immunodeficiency Bigley et al.compartment, loss of peripheral blood and tissue
mononuclear cells (dendritic cell, monocyte, B and
NK cells deficiency; DCML deficiency), associated
with a high serum Flt3 ligand, is an almost universal
finding at presentation [36] although de-novo acute
myeloid leukaemia (AML) can develop without prior
clinical immunodeficiency [34]. Interestingly, tissue
macrophages and epidermal lymphoid cells are rela-
tively preserved, in keeping with their independence
from blood borne precursors [37]. Presentation of
GATA2 mutation in childhood is often related to
myelodysplasia (MDS)/chronic myelomonocytic leu-
kaemia (CMML), (particularly associated with
monosomy 7), although prior or concurrent immu-
nodeficiency features may be elicited [38
&&
]. In adults,
primary immunodeficiency may be a more promi-
nent feature with susceptibility to mycobacterial,
viral (human papillomavirus) and fungal infection,
autoimmunity, and respiratory compromise due to
recurrent bacterial infections and/or pulmonary
alveolar proteinosis. Development of MDS/AML (in
approximately 50% of patients) is associated with the
acquisition of additional cytogenetic (monosomy 7/
8) or molecular genetic abnormalities [39] and devel-
opment of additional cytopenias or CMML-like fea-
tures. In patients who do not develop early MDS/
AML, survival into adulthood is likely to be facilitated
by immune memory developed by a relatively intact
immune system in childhood with normal class-
switched immunoglobulin, grossly intact T cell com-
partment, and normal responses to childhood
vaccines. Although many GATA2 mutations have
been described, there is little correlation between
genotype and phenotype as members of the same
family can be present with different clinical pictures.
The influence of genetic background, effect of
additional constitutive or acquired mutations, and
environmental exposure on the pathogenesis and
clinical phenotype are yet to be fully elucidated.Interferon regulatory factor 8 mutations
The IRFs are classic examples of single genes expressed
in multiple functional gene sets as they are involved
not only in interferon signaling, inflammation, and
regulation of cytokine production but also have
critical roles in hematopoietic cell differentiation
[40,41]. IRF8 (interferon consensus sequence-binding
protein; ICSBP) is necessary for the differentiation of
allmonocyteanddendritic cell subsets,withdepletion
of these subset equivalents in a mouse model bearing a
targeted null allele [42–44]. The BXH2 mouse model,
carrying a hypomorphic IRF8R294C mutation [45]
shows depletion of predominantly cDC1s and to a
lesser extent pDCs [46]. Both models show impaired
IL-12 production inthe context of myeloproliferation. Copyright © 2016 Wolters Kluwe
1528-4050 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseIRF8 is a key player in the IFNg/IL-12 axis [47],
particularly important for resistance to mycobacte-
rial infection [48]. It regulates many critical
elements, including the differentiation of mono-
cytes/dendritic cells, the production of IFNg from
T cells and IL-12 from myeloid cells, the transcrip-
tional response to these cytokines, and the relevant
polarization of T cells [49–51]. The central role of
IRF8 illustrates the concept that single immune
genes determine the response to specific classes of
pathogen by coordinating multiple pathways in
many different cell types.
Myeloproliferation observed in IRF8 deficiency
likely results from a number of mechanisms includ-
ing the failure to block the pro-granulopoietic
effects of C/EBPa [52], and failure to terminate
emergency hematopoiesis following an infectious
stimulus [53].
In humans, biallelic IRF8 deficiency has been
described in one individual with autosomal reces-
sive K108E mutation, presenting at 10 weeks of age
with disseminated BCG (Bacillus Calmette-Gue´rin)
infection following vaccination, oral candidiasis,
cachexia, and intracerebral calcification [35], sub-
sequently associated with developmental delay. In
keeping with IRF8 deficient mice, all monocyte and
dendritic cell subsets were absent in the context of
marked myeloproliferation. The severe immune
defect necessitated stem cell transplantation, which
resulted in complete donor cell repopulation of the
APC compartment, in blood and tissues, and resol-
ution of BCG infection and myeloproliferation.
Autosomal dominant T80A mutation was identi-
fied from a cohort of adult patients with mycobacte-
rial infection. Analysis of themonocyte/dendritic cell
compartment revealed a subtle defect in CD1c
expression on cDC2s, which is at odds with the
relative dependence of cDC1 and pDC on IRF8 in
mouse. This contradiction may be related to differ-
ences in the specific mutation in IRF8, or divergence
in function of apparently homologous subsets
between the two species. In both clinical cases, myco-
bacterial infection responded to chemotherapy, life
expectancy was not affected, and stem cell transplan-
tation was not required.Quantitative dendritic cell deficiency in other
known disorders
Reticular dysgenesis, due to mutations in adenylate
kinase 2 (AK2), results in severe pancytopenia which
includes monocytes, dendritic cells, and lymphoid
cells [54–56].
WHIM (warts, hypogammaglobulinemia, immu-
nodeficiency, and myelokathexis) presents as a
progressive immunodeficiency. CXCR4 mutationr Health, Inc. All rights reserved.
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leaving the bone marrow resulting in neutropenia
and deficiency, but not absence, of monocytes and
dendritic cells [58].
Ikaros/IKZF1 mutation in a single reported case
describes a severe pancytopenia affecting mono-
cytes and probably dendritic cells [59]. However, a
recent paper [60] describes 29 individuals from six
families with heterozygous IKZF1 mutations and a
predominant phenotype of low serum immuno-
globulin and progressive B cell loss without overt
pancytopenia. As IKZF1 is required for pDC differ-
entiation in mouse [61], these cases may reveal more
subtle defects in dendritic cells.
Neutropenic states involve genes implicated in
dendritic cell development in mice, including GFI1
[62] and ELANE (congenital and cyclical neutrope-
nia) [63] but the effect of these mutations on den-
dritic cells has not yet been assessed.Defects of dendritic cell function
Bare lymphocyte syndrome, caused by mutations in
CIITA, RFXANK, RFX5, or RFXAP [64], is a severe
immunodeficiency due to lack of MHC class II
expression characterized by recurrent bacterial
infection, chronic viral infections, failure to thrive,
and death before the age of 10 years. Deficient Ag
presentation leads to reduced numbers of CD4þ T
cells and failure to mount effective CD4þ T cell
responses or make immunoglobulin in response to
vaccines [65].
Wiskott-Aldrich syndrome (WAS), caused by
mutations in a cytoskeletal protein, WAS protein
(WASp), affects dendritic cell migration and
immune synapse formation with T cells [66] but
may enhance dendritic cell cross-presentation
[67]. Impaired T cell and antibody responses result
in the risk of recurrent severe infection. Additional
features include atopia, autoimmune hemolysis,
vasculitis, and thrombocytopenia [68].
CD40/CD40L deficiency results in defective iso-
type switching and impaired dendritic cell signal-
ing, cytokine production, and cross-presentation
[69,70].
Pitt-Hopkins Syndrome, associated with
mutations in the transcription factor E2-2 (TCF4),
although not classified as PID, impairs in-vitro
responses of pDCs [23]. A recent study [71] revealed
recurrent infection in 35% of patients. Additional
features include typical facies, intellectual disability,
and epilepsy.
STAT3 mutation (signal transducer and activa-
tor of transcription 3) in humans is not associated
with numerical loss of dendritic cells but responses
to IL-10 are impaired [72]. Copyright © 2016 Wolters Kluwer 
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pound heterozygous patient, results in severe influ-
enza infection, attributed to impaired IFN type I and
III production by pDCs [73
&&
].ANALYSIS OF DENDRITIC CELLS IN
PRIMARY IMMUNODEFICIENCY DISEASE
The potential of dendritic cell and monocyte
analysis to assist in the clinical diagnosis and under-
standing of PID is only just being realized [74].
Simplistically speaking, the hematopoietic origin
of dendritic cells lies between lymphoid and
myeloid cells and dendritic cell number and func-
tion may be perturbed in association with defects of
either lineage. Identifying perturbations in the den-
dritic cell/monocyte compartment may help to
confirm the existence of an immune dysfunction,
understand a phenotype, predict response to vacci-
nation, or guide the analysis of next generation
sequencing investigations.
Diagnosis of known dendritic cell deficiency
syndromes: Myeloproliferation of biallelic IRF8
deficiency may mask the absolute monocytopenia
on automated blood counters but absence of den-
dritic cells and monocytes in this context is, to date,
pathognomonic. Depth of mononuclear cell loss,
together with increase in serum Flt3L, in GATA2
mutation may inform ‘stage’ of disease and associate
with development of symptoms or progression to
bone marrow failure.
Discovering novel dendritic cell deficiency syn-
dromes: Analysis of the recently described ‘human
gene connectome’ (HCG) [75] has identified novel
candidate PID-causing genes based on their bio-
logical proximity to known causative genes [76
&
].
This work predicts that PID may be caused by
mutations in many genes related to dendritic cell
differentiation or function including KLF4, ID2,
IRF4, RUNX1, RUNX2, and TLRs.
Understanding dendritic cells in known primary
immunodeficiency diseases: Dendritic cell
deficiency or dysfunction may contribute to the
diagnosis and phenotype of many known PIDs, in
which functions of the mutated gene have not yet
been explored beyond lymphocytes, for example
TLR3 [16], TRAF3 [77], and ADA [78].A practical approach to analysis
Dendritic cells are too rare to enumerate morpho-
logically by cytological examination of whole blood
and automated blood counters are unable to
distinguish dendritic cells from lymphocytes by
light scatter properties (Fig. 3a). Classical, but
not nonclassical, monocytes can be identifiedHealth, Inc. All rights reserved.
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(b) 8-color (10-channel) flow cytometry to identify monocyte and dendritic cell populations in blood, together with their
morphological appearance after fluorescence activated cell sorting (FACS), cytospin, and Giemsa staining. (c) Diagrammatic
representation of adapted lymphocyte subset panel utilizing CD4 expression on APCs to distinguish them from lymphocytes
when APC/lymphocyte antigens are combined in one fluorescent channel. (d) Flow cytometric gating strategy to identify T, B,
and NK lymphocytes alongside classical and nonclassical monocytes.
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Primary immune deficiency diseasemorphologically and on automated counters but
monocytopenia can be masked by the appearance
of immature myeloid cells with similar light scatter
properties. As such, ‘first line’ hematological inves-
tigations are unable to identify dendritic cell
deficiency and may underestimate monocytopenia.
Flow cytometry lends itself well to clinical den-
dritic cell/monocyte analysis as it allows accurate
identification and enumeration of rare populations
of cells from clinically appropriate volumes of
blood. A minimum of six channels is required to
identify all monocyte and dendritic cell subsets,
including human leukocyte antigen-DR (HLA-DR)
expressed on all APCs, lymphocyte lineage markers
to exclude HLA-DRþ T-, B-, NK-cells, and CD34þ
progenitor cells, CD14 and CD16 for monocyte
analysis, CD123 or CD303/CD304 for pDC,
CD141 or Clec9A for cDC1, and CD1c/BDCA1 for
cDC2 (Fig. 3b). With a view to minimizing sample
volumes and costs, a protocol has been devised to
combine dendritic cell analysis with standard
lymphocyte subset enumeration panels (Fig. 3c
and d). This panel relies on the universal expression
of CD4 by APCs, allowing segregation of dendritic
cell/monocytes from lymphocytes using standard
markers alone (CD3, CD4þ cells). Further refine-
ment is possible by combining one lymphocyte and
one APC antibody in a single fluorescence detection
channel to pull out monocyte subsets and to separ-
ate pDCs from cDCs [79].
Functional analysis poses more significant prob-
lems, given the broad array of pathogen receptors,
costimulatory molecules, and potential cell outputs
of different dendritic cell subsets, such that it is
unlikely to be possible to interrogate all aspects of
dendritic cell function in a single reaction. Whole
blood cytokine analysis is well described, particu-
larly for investigating the IL-12/IFNg axis [80] but
cell-specific dendritic cell/monocyte functional
analysis is currently confined to the research labora-
tory.Whom to test
Ideally, patients with a high clinical index of suspi-
cion for a dendritic cell deficiency would be selected
for testing. However there are a number of obstacles
to this approach.
First, given the complexities of the integrated
immune system, it may not be possible to closely
define this clinical category. Some (nonspecific)
features of global monocyte and dendritic cell loss
can be inferred from IRF8 and GATA2 mutations and
these would include susceptibility to tuberculosis
and atypical mycobacteria, viral infection (particu-
larly HPV and herpes simplex virus), pulmonary Copyright © 2016 Wolters Kluwer 
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and pulmonary alveolar proteinosis), and auto-
immunity. Specific features of these mutations
may also be sought, such as myeloproliferation in
biallelic IRF8 mutation and MDS or extrahemato-
poietic features in GATA2 mutation.
Second, it is difficult, at present, to define the
pretest risk without a better picture of the preva-
lence, which will only be achieved through much
greater uptake of dendritic cell and monocyte
enumeration by diagnostic laboratories.
We suggest, therefore, that a survey level
analysis (six-color flow cytometry) should be per-
formed in all new patients with suspected immuno-
deficiency alongside, for example, T and B cell
subset analysis. An abnormal screen or a high index
of suspicion should prompt full immunophenotyp-
ing of myeloid mononuclear cells.
This will facilitate the discovery of novel den-
dritic cell and monocyte disorders as well as build a
picture of the dendritic cell/monocyte landscape in
PID specifically and in immunity generally.CONCLUSION
Mouse models have suggested that dendritic cells
are critical to initiate and maintain immunity and
tolerance, yet little attention has been paid to their
contribution in PID. Recent descriptions of den-
dritic cell deficiencies and dysfunctions in the con-
text of immunodeficiency have highlighted their
importance in this field. Clinical level screening
for dendritic cell and monocyte defects will allow
the identification of novel disorders and aid the
diagnosis and pathophysiological understanding
of immunodeficiency.
From a research perspective, through the coordi-
nated investigation of dendritic cells in patients with
immunodeficiency, the PID community is in a
unique position to advance our understanding of
the function of human dendritic cells and monocytes
in vivo, looking to harness their immune potential for
therapeutics across wider fields of medicine.
Aligning these efforts with those of next gener-
ation sequencing consortia such as the NIHR
BRIDGE Project (PID) (https://bridgestudy.
medschl.cam.ac.uk/pid.shtml) and 100,000
Genome Project (https://www.genomicsengland.
co.uk), with the support of cohesive research net-
works such as the Genomics England Clinical
Interpretation Partnership (GeCIP), will likely yield
fruitful results.
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